Pamrevlumab Trials

Pamrevlumab, our proprietary fully human antibody, targets connective tissue growth factor (CTGF), the central mediator of tissue remodeling and fibrosis. Pamrevlumab represents a potential treatment for a broad array of fibrotic and proliferative disorders that affect organ systems throughout the body. Pamrevlumab is in Phase 3 clinical studies for the treatment idiopathic pulmonary fibrosis, pancreatic cancer, and in Phase 2 for Duchenne muscular dystrophy.